GlassScriptPhysician profile
Eddie Flores
NPI 1568466217
$4,885.51
in general payments reported to CMS, 2019-2025
36 companies · $649 in 2025
The $649 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $352 · 2021: $675 · 2022: $1,066 · 2023: $930 · 2024: $679 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $18.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.99 |
| Education | $18.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,394.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $473.65 | 2019-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $419.28 | 2021-2025 | Stelara, Tremfya |
| Celgene Corporation | $377.25 | 2021-2023 | Zeposia |
| Pfizer INC. | $195.05 | 2019-2023 | |
| Lilly USA, LLC | $179.41 | 2023-2025 | Omvoh |
| Olympus America INC. | $164.55 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.39 | 2019-2025 | Eohilia, Gattex |
| Redhill Biopharma INC. | $134.38 | 2020-2024 | Talicia |
| Shionogi INC | $129.46 | 2019 | |
| Ferring Pharmaceuticals INC. | $124.62 | 2019-2023 | Rebyota |
| Qol Medical, LLC | $107.28 | 2020-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $97.00 | 2019-2023 | Dificid |
| Medtronic Vascular, INC. | $96.99 | 2019 | |
| Daiichi Sankyo INC. | $91.76 | 2019-2025 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $87.99 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $79.00 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $78.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $75.26 | 2022-2024 | |
| Micro-Tech Endoscopy USA, INC. | $68.11 | 2021-2023 | Balloons |
| Aimmune Therapeutics, INC. | $45.71 | 2024-2025 | Vowst, Zenpep |
| Ardelyx, INC. | $34.73 | 2023-2024 | Ibsrela |
| Gilead Sciences, INC. | $33.54 | 2021-2025 | |
| Covidien LP | $29.40 | 2020 | |
| Phathom Pharmaceuticals, INC. | $28.97 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $27.44 | 2019-2021 | |
| American Regent | $21.82 | 2025 | Injectafer |
| Celltrion USA INC. | $18.79 | 2024 | Zymfentra |
| Janssen Pharmaceuticals, INC | $18.73 | 2022 | |
| Braintree Laboratories, INC. | $17.31 | 2021 | |
| Exact Sciences Corporation | $16.53 | 2025 | The Cologuard Plus Collection Kit |
| Evoke Pharma, INC. | $16.44 | 2023 | Gimoti |
| Medtronic, INC. | $15.32 | 2024 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $12.14 | 2022 | |
| Alfasigma USA, INC. | $11.68 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$35,088.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.